Neoleukin Therapeutics Q1 Loss Widens, Operating Expenses Rise
08:57 AM EDT, 05/12/2021 (MT Newswires) -- Neoleukin Therapeutics (NLTX) posted a Q1 loss Wednesday of $0.27 per share, compared with a loss of $0.18 per share a year earlier.
Analysts polled by Capital IQ projected a loss of $0.23 per share.
Operating expenses were $14.9 million for the quarter ended March 31, up from $9.1 million a year ago.
As of March 31, Neoleukin had $178.4 million in cash and cash equivalents, compared with $192.6 million on Dec. 31. The biopharmaceutical firm said it has sufficient cash to fund operations into 2023.
Price: 11.40, Change: 0.00, Percent Change: 0.00